Developer of new therapies and medical devices intended to treat sinus health problems. The company's new therapies and medical devices use proprietary osmotic technology to develop dilation devices for the treatment of frontal and sphenoid sinus and other ENT problems, enabling patients to avail effective and reliable treatments.
Startup
Privately Held (backing)
Venture Capital-Backed
The company raised $6.78 million of Series D venture funding from Altos Health Management, AshHill Biomedical and Emergent Medical Partners on September 04, 2014, putting the company's pre-money valuation at $23.46 million. Life Science Angels and other undisclosed investors also participated in the round.
Add a review